Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121591) titled 'A Phase I Dose-Escalation Clinical Study Evaluating Stiripentol Combined with Immunochemotherapy for the Treatment of HER2-Negative Unresectable Advanced Gastric Cancer' on April 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen)
Condition:
Treatment-naive HER2-negative unresectable advanced gastric cancer
Recruitment Status: Not Recruiting
Phase: 1
Date of First Enrollment: 2026-04-01
Target Sample Size: Experimental group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.c...